Home / Centerstage / 2015 / February / Week 3 /
Valeant Pharmaceuticals announces its acquisition of Salix Pharmaceuticals for approximately $10 billion in cash. This deal marks Valeant's return to significant deal-making after its unsuccessful attempt to acquire Allergan in the previous year. The acquisition of Salix Pharmaceuticals aligns with Valeant's growth strategy and expands its presence in the pharmaceutical industry, contributing to its long-term objectives and market position.
Saturday, 21 February, 2015